QUÉBEC CITY, Feb. 3,
2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that presentations
on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108)
and disorazol Z, will be made during the 11th
International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
The session will be held on Tuesday,
February 11, 2014, in Hall A of the Wyndham Hotel in
Salzburg.
Presentations are scheduled as follows:
| 10:30 am |
"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting
Concept: Overview of Clinical Results" |
| |
Speaker: Dr. Günter Emons, Chairman, Department of Obstetrics
& Gynaecology, Georg-August University Göttingen, Germany |
| |
|
| 11:00 am |
"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting
Concept: GnRH Receptor Targeting in Triple-Negative Breast
Cancer" |
| |
Speaker: Dr. Jörg B. Engel, Medical University of Regensburg,
Department of Gynaecology and Obstetrics, Germany |
| |
|
| 11:15 am |
"New and Highly Potent Disorazol Z GnRH Conjugates: Concept
and Mode of Action" |
| |
Speaker: Dr. Babette Aicher, Director, Preclinical Development,
Aeterna Zentaris |
| |
|
| 11:45 am |
"New and Highly Potent Disorazol Z GnRH Conjugates:
Preclinical Results in Endometrial Cancers" |
| |
Speaker: Dr. Carsten Gruendker, Department of Obstetrics &
Gynaecology, Georg-August University Göttingen, Germany |
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds from
drug discovery to regulatory approval. For more information, visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and
U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The
Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.